. Author manuscript; available in PMC: 2024 Feb 27.

Published in final edited form as: Lancet Infect Dis. 2016 Jul 7;16(10):1134–1144. doi: 10.1016/S1473-3099(16)30161-X

Table 4:

Proportion of participants with seropositivity and geometric mean titres for anti-circumsporozoite antibodies

	N	≥0·5 EU/mL	GMT (95% CI)

RTS,S/AS01 vaccine
Screening	81	16 (20%), 11·7–30·1	0·3 (0·3–0·4)
1 month after dose 3	79	79 (100%), 95·4–100	329·2 (260·6–415·8)
12 months after dose 3	73	72 (99%), 92·6–100	18·4 (13·3–25·5)
Rabies vaccine
Screening	73	13 (18%), 9·8–28·5	0·3 (0·3–0·4)
1 month after dose 3	71	9 (13%), 6·0–22·7	0·3 (0·3–0·3)
12 months after dose 3	67	6 (9%), 3·4–18·5	0·3 (0·3–0·3)

Data are n (%), 95% CI, or geometric mean antibody titre (GMT; 95% CI) taken from the according-to-protocol population for immunogenicity. EU=enzyme-linked immunosorbent assay unit. N=number of children with available results.